Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Evogene (EVGN) Research & Development (2016 - 2025)

Historic Research & Development for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to $1.4 million.

  • Evogene's Research & Development fell 5839.64% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 3767.01%. This contributed to the annual value of $12.5 million for FY2024, which is 3978.44% down from last year.
  • According to the latest figures from Q3 2025, Evogene's Research & Development is $1.4 million, which was down 5839.64% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Evogene's Research & Development ranged from a high of $6.0 million in Q4 2021 and a low of $1.4 million during Q3 2025
  • Moreover, its 5-year median value for Research & Development was $4.8 million (2024), whereas its average is $4.4 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 4572.29% in 2021, then crashed by 5839.64% in 2025.
  • Quarter analysis of 5 years shows Evogene's Research & Development stood at $6.0 million in 2021, then dropped by 20.99% to $4.8 million in 2022, then rose by 16.66% to $5.5 million in 2023, then plummeted by 38.67% to $3.4 million in 2024, then crashed by 59.57% to $1.4 million in 2025.
  • Its Research & Development stands at $1.4 million for Q3 2025, versus $2.3 million for Q2 2025 and $3.2 million for Q1 2025.